pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Launches Rare Disease Framework Initiative ]]>

Read source
natlawreview.com /1 month ago

FDA Opens Applications for New Pilot to Shorten Drug Approval Times: What Sponsors Need to Know

Earlier this month, FDA opened applications for a new Expedited Investigational New Drug (IND) Pilot Program (the “Program”), an initiative launched under HHS Operation TrialBlazer...

Read source
biopharmadive.com /1 month ago

FDA ‘reset’ continues with new plan for reviewing rare disease drugs

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

Read source
orthotw.com /1 week ago

NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury

Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to INOVIO’s Voceryq for RRP, Reducing Surgical Burden]]>

Read source
biopharmadive.com /3 weeks ago

FDA unveils guidance for ‘plug and play’ gene therapies

The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same diseas...

Read source
biopharmadive.com /1 month ago

FDA starts review of Roche’s multiple sclerosis pill

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

Read source
multiplesclerosisnewstoday.com /1 month ago

FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Roche seeking approval of its BTK inhibitor fenebrutinib as a treatment for relapsing forms of...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli]]>

Read source
healio.com /1 month ago

FDA approves Atebrioz for fibrodysplasia ossificans progressiva

Editor’s note: This is a developing story. Please check back soon for updates.The FDA approved zilurgisertib tablets for the reduction of heterotopic ossification among patients ag...

Read source
pharmexec.com /5 days ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Three New Therapies]]>

Read source
investing.com /1 month ago

vTv Therapeutics stock jumps on FDA orphan drug status

Read source
biopharmadive.com /1 month ago

Grail multicancer detection test wins FDA advisers’ backing

Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

Read source
pharmexec.com /4 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B]]>

Read source
pharmexec.com /1 week ago

<![CDATA[FDA Approves Pimjetmi for Patients With Tenosynovial Giant Cell Tumor]]>

Read source
thefdalawblog.com /1 month ago

Rare Disease Refresh: FDA’s Rare Disease Framework Initiative

By James E. Valentine & Charles G. Raver & Frank J. Sasinowski —

Read source
orthotw.com /1 month ago

VB Spine Announces FDA Breakthrough Device Designation for New Blood Test Designed to Identify Patients at Risk for Scol...

VB Spine LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ScolimiR-3D.

Read source
pharmexec.com /1 week ago

<![CDATA[FDA Approves asundexian for Secondary Stroke Risk Reduction ]]>

Read source
pharmexec.com /4 weeks ago

<![CDATA[FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease]]>

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.